Bristol-Myers Squibb Company

Release Summary

Encouraging disease control rates observed w/ nivolumab alone or in combination with ipilimumab in refractory or relapsing Malignant Pleural Mesothelioma patients: Results from IFCT-1501 MAPS2 trial

Bristol-Myers Squibb Company